title: Efficacy and tolerability of indiplon in transient insomnia.
abstract: OBJECTIVE
  The efficacy of indiplon was evaluated by polysomnography (PSG) in an experimental model of transient insomnia consisting of the first night effect combined with a 2-hour phase advance.
  
  
  METHODS
  Healthy volunteers age 21-64 years (N=593; 62% female; mean +/- SEM) years, 32 +/- 0.39) were randomized to double-blind treatment with a single nighttime dose of indiplon (10 mg or 20 mg) or placebo. PSG assessments included latency to persistent sleep (LPS, primary endpoint) and total sleep time (TST); self-report assessments included sleep quality (SQ); next day residual effects were evaluated by the Digit Symbol Substitution Test (DSST), Symbol Copying Test (SCT), and a Visual Analog Scale of sleepiness (VAS).
  
  
  RESULTS
  LPS mean (+/- SEM) values were significantly reduced on indiplon 10 mg (21.2 +/- 1.5 minutes) and indiplon 20 mg (16.8 +/- 1.1 minutes) compared to placebo (33.1 +/- 2.5 minutes; p < 0.0001 for both comparisons to placebo). TST mean (+/- SEM) values were significantly increased on indiplon 10 mg (414.5 +/- 3.9 minutes) and indiplon 20 mg (423.5 +/- 3.1 minutes) compared to placebo (402.9 +/- 3.9 minutes; p <0.005 for the 10 mg dose; p < 0.0001 for the 20 mg dose). SQ was also significantly improved on both doses. There were no differences between indiplon and placebo on next day DSST, SCT, or VAS.
  
  
  CONCLUSIONS
  Indiplon was effective in inducing sleep, increasing sleep duration, and improving overall sleep quality without next day residual effects in healthy volunteers in a model of transient insomnia.
authors: Atlanta Sleep Institute, Atlanta, GA 30342, USA. russell.rosenberg@atlantasleep.com
authors: Russell
authors: R
authors: Rosenberg
authors: Thomas
authors: T
authors: Roth
authors: Martin B
authors: MB
authors: Scharf
authors: D Alan
authors: DA
authors: Lankford
authors: Robert
authors: R
authors: Farber
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017286:Polysomnography / Q000379:methods; D012016:Reference Values; D012650:Self Disclosure; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D006993:Hypnotics and Sedatives; D013876:Thiophenes; D001569:Benzodiazepines; C469870:indiplon
references: Curr Med Res Opin. 2004 Apr;20(4):441-9
references: 15119980
references: Sleep. 1996 Apr;19(3 Suppl):S7-15
references: 8723370
references: Sleep. 1997 Sep;20(9):715-23
references: 9406323
references: Int J Clin Pract. 2001 Jan-Feb;55(1):42-52
references: 11219318
references: Sleep. 2004 Mar 15;27(2):285-91
references: 15124724
references: J Sleep Res. 2000 Mar;9(1):35-42
references: 10733687
references: Am Fam Physician. 1999 Jun;59(11):3029-38
references: 10392587
references: Psychophysiology. 1966 Jan;2(3):263-6
references: 5903579
references: J Clin Pharmacol. 1978 Feb-Mar;18(2-3):110-8
references: 342551
references: Clin Cornerstone. 2003;5(3):5-15
references: 14626537
references: Science. 1977 Nov 25;198(4319):847-8
references: 21453
references: Sleep. 2003 Dec 15;26(8):1029-36
references: 14746386
references: Arzneimittelforschung. 1990 Aug;40(8):859-62
references: 2242077
references: J Clin Psychiatry. 1992 Jun;53 Suppl:19-22
references: 1613015
references: Sleep. 1995 May;18(4):246-51
references: 7618022
references: J Clin Psychopharmacol. 1990 Jun;10(3):184-9
references: 2198296
references: Hum Psychopharmacol. 2001 Mar;16(2):169-176
references: 12404587